Reviewer’s report

Title: Vedolizumab Trough Level Monitoring In Inflammatory Bowel Disease: A State Of The Art Overview

Version: 0 Date: 28 Jan 2019

Reviewer: Pilar Nos

Reviewer’s report:

The review is adequate, the subject treated: knowledge about the levels of vedolizumab and its monitoring in inflammatory bowel disease is very well focused on the abstract and on the background.

Some minor comments

In the line 51-52 (background) is more adequate, in my opinion review than commentary.

In Current Knowledge:

Line 10 the value is in expressed and $\alpha$ and should be expressed in $\mu$. It seems a mistake.

We suggest to add the recent reference, for reasons of time it has not been referred because it has just been published, but we believe that it would enrich the end of the section.


Vedolizumab exposure levels and clinical outcomes in ulcerative colitis:

determining the potential for dose optimisation.

In these study a propensity-score-based case-matching analysis was performed using data from GEMINI I and an earlier large population pharmacokinetic study, with vedolizumab clearance or concentration as predictors of clinical remission and response, adjusted for age, weight, anti-tumour necrosis factor alpha therapy history, serum albumin and faecal calprotectin concentrations. Potential vedolizumab concentration targets at weeks 6, 14 and steady state were proposed. Association between early vedolizumab concentrations at weeks 2, 4 and 6 and clinical remission at weeks 14 and 52 was evaluated.

At the end of the review, future prospects are set out in a very appropriate and concise manner.
Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

Educational activities, research projects, scientific meetings and advisory boards sponsored by Abbvie, MSD, Janssen, Ferring, Faes, Otsuka, Takeda and Tillots.

Since October 2017 (chairmanship of the Spanish working group on Crohn and Colitis: GETECCU) without conflict of interest.

Statement on potential review bias
Please complete a statement on potential review bias, considering the following questions:

1. Did you co-author any publication with an author of this manuscript in the last 5 years?

2. Are you currently or recently affiliated at the same institution as an author of this manuscript?

If you can answer no to all of the above, write 'I declare that I did not publish with these authors in the last 5 years and also meet the affiliation criteria". If your reply is yes to any, please give details below.
I declare that I did not publish with these authors in the last 5 years and also meet the affiliation criteria.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal.